Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505524 | 0.75 | PNP (0.40) | PNP | |
| SCHEMBL505570 | 0.72 | PNP (0.65) | PNP | |
| Hydrochloric Acid SCHEMBL4841864 | 0.71 | PNP (0.64) | PNP | |
| SCHEMBL15740137 | 0.66 | PNP (0.64) | PNP | |
| SCHEMBL19671128 | 0.66 | PNP (0.64) | PNP | |
| SCHEMBL505891 | 0.60 | PNP (0.65) | PNP | |
| Hydrochloric Acid SCHEMBL4840187 | 0.59 | PNP (0.64) | PNP | |
| SCHEMBL4834034 | 0.59 | PNP (0.61) | PNP | |
| SCHEMBL4839877 | 0.59 | PNP (0.40) | PNP | |
| SCHEMBL506021 | 0.58 | PNP (0.39) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9241916-B2 | Cognitive performance with sirtuin activators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| US-8846724-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-30 | — | — | US | disclosed |
| US-8242171-B2 | Method for reducing the weight of a subject or inhibiting weight gain in a subject | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-02-02 | — | — | US | disclosed |
| US-8017634-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2361618-A2 | Compositions for treating or preventing obesity and insulin resistance disorders | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20080194803-A1 | Cognitive Performance With Sirtuin Activators | HOWARD HUGHES MEDICAL INSTITUTE | 2008-08-14 | — | — | US | disclosed |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRTRIS PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060292099-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-20060276416-A1 | Methods and compositions for treating flushing and drug induced weight gain | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-25 | — | — | US | disclosed |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-04 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | FABP4, PLIN1, SIRT1 | PNP 3367/4885 |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PNP 3921/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | PNP 1/4885 |
| US-20060276416-A1 | Methods and compositions for treating flushing and drug induced weight gain | SIRT2, SIRT1, SIRT7 | PNP 3378/4885 |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRT1, SIRT2, SIRT3 | PNP 4397/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | PNP 4175/4885 |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRT2, SIRT1, SIRT3 | PNP 3481/4885 |
| US-20060292099-A1 | Treatment of eye disorders with sirtuin modulators | SIRT1, SIRT2, SIRT3 | PNP 4397/4885 |
| US-20080194803-A1 | Cognitive Performance With Sirtuin Activators | SIRT1, SIRT2, SIRT7 | PNP 2309/4885 |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PNP 3921/4885 |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRT1, SIRT3, SIRT2 | PNP 2885/4885 |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | FABP4, GPR119, SIRT1 | PNP 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.